[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-mediastinal-large-b-cell-lymphoma-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-mediastinal-large-b-cell-lymphoma-recurrent":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100570180","phase-1-a-study-to-evaluate-the-safety-and-clinical-activity-of-gf--cart01-cd2019-car-t-cell-in-subjects-with-relapsed-or-refractory-b-cell-hematological-malignancies-100570180",false,"NCT06703892","A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20\u002F19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies","An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20\u002F19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies","CD20\u002F19 CAR T","Inclusion Criteria:\n\n1. Subjects must be of age ≥ 18 years and ≤ 70 years\n2. Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent\n3. Histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma - Not Otherwise Specified (DLBCL-NOS), follicular lymphoma (FL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), or High-Grade B-Cell Lymphoma (HGBCL) per the world health organization (WHO) Classification Criteria for Lymphoma (2022)\n4. Tumor cell surface expression of CD19 (+) and\u002For CD20 (+) by flow cytometry or immunohistochemistry staining\n5. Relapsed, progressive or refractory disease (defined as have not achieved a complete response) after ≥ two lines of systemic therapy, including anti-CD20 antibody and anthracycline and\u002For Relapsed, progressive or refractory disease ( defined as have not achieved a complete response) after auto-HSCT\n6. Subjects have any accessible PET-positive lesion or measurable CT-positive lesion per Lugano 2014 criteria\n7. Adequate hematologic function: absolute neutrophil count (ANC) \\> 1,000\u002FμL, absolute lymphocyte count (ALC) \\> 300\u002FμL, platelet count ≥ 75,000\u002FμL, hemoglobin ≥ 8.0 g\u002FdL\n8. Adequate hepatic function: alanine aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN), aspartate transaminase (AST) ≤ 5 times ULN, total bilirubin ≤ 1.5 times ULN\n9. Adequate renal function: blood estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73m2 (calculated by Modification of Diet in Renal Disease (MDRD) equation)\n10. Adequate cardiac function: echocardiogram or multigated blood pool analysis (MUGA) shows left ventricular ejection fraction (LVEF) ≥ 50%; and no clinically significant electrocardiogram (ECG) findings\n11. Adequate pulmonary function: no active infection in the lungs, blood oxygen saturation in indoor air ≥ 92%\n12. No clinically significant pleural effusion determined by the investigators\n13. Estimated survival time ≥ 3 months\n14. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n15. Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement\n\nExclusion Criteria:\n\n1. Previously treated with any CAR T cell product or allogenic hematopoietic stem cell transplant (HSCT)\n2. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of the investigational product (IP)\n3. Known medical history or possible risk for taking contrast agent(s) for positron emission tomography (PET) and\u002For computed tomography (CT) scan\n4. Received any other investigational product, cell therapy, or gene therapy within 12 weeks prior to the leukapheresis\n5. Received any tyrosine kinase inhibitor within 2 weeks prior to the leukapheresis\n6. Received any systemic steroid, immunotherapy (such as immune checkpoint inhibitors, T- cell transfer therapies, monoclonal antibodies), or chemotherapy within 4 weeks prior to the leukapheresis\n7. Received any live vaccine from 2 weeks prior to the leukapheresis\n8. Subjects with human immunodeficiency virus (HIV), syphilis, Hepatitis B or C infection: HIV-1 and HIV-2 antibody positive, syphilis antibody positive, both hepatitis B virus (HBV) DNA and hepatitis B core (HBc) antibody positive, or hepatitis C virus (HCV) antibody positive\n9. Subjects with atrial or ventricular involvement by B-cell malignancies\n10. Subjects with tumor mass requiring urgent treatment within 8 weeks prior to the leukapheresis, such as ileus, tumor lysis syndrome, or vascular compression\n11. Subjects with severe disease or other uncontrolled diseases, such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia (urgent intervention indicated, life- threatening consequences, or hemodynamic compromise), cardiac angioplasty or stenting, unstable angina, cerebral thrombosis, cerebral hemorrhage, hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg)\n12. Unstable pulmonary embolism, deep venous embolism, or other major arterial\u002Fvenous thromboembolism events that occurred within 6 weeks prior to the leukapheresis. If subjects receive anticoagulant therapy, the treatment dose and frequency must be stable for more than 14 weeks prior to the leukapheresis\n13. History of craniocerebral trauma, disturbance of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic diseases, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement\n14. Female subject of childbearing potential who: a. Has positive pregnancy test result; or b. Is lactating\n15. Female subjects of childbearing potential, or male subject with female spouse\u002Fpartner of childbearing potential, who refuses to adopt at least one form of birth control from the date of signing informed consent to 12 months after GF-CART01 infusion. Acceptable forms of birth control include: a. Established use of oral, injected or implanted hormonal methods of contraception b. Placement of an intrauterine device (IUD) or intrauterine system (IUS) c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps)\n16. Any following situations that the investigators believe are not suitable for this trial and\u002For may increase the risk for subjects or interfere with the results of the study a. With severe active infections (except simple urinary tract infection and bacterial pharyngitis) b. With active central nervous system involvement by lymphoma, malignant cells in cerebrospinal fluid c. History of brain metastasis d. With uncontrolled malignancies e. Any toxicities due to prior therapy f. With any uncontrolled illness or a history of any illness","ALL","18 Years","70 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R\u002FR) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-hematopoietic stem cell transplantation (HSCT).This study is a traditional 3+3 dose-escalation design to observe dose-limiting toxicity (DLT), establish the maximum tolerated dose(MTD)\u002Frecommended phase 2 doses (RP2D), and preliminary efficacy of GF-CART01. RP2D may equal to or lower than MTD",[28,29,30,31,32,33],"Diffuse Large B Cell Lymphoma Relapsed","Diffuse Large B Cell Lymphoma Refractory","Follicular Lymphoma ( FL)","Primary Mediastinal Large B-Cell Lymphoma-Refractory","Primary Mediastinal Large B-Cell Lymphoma-Recurrent","High-grade B-cell Lymphoma (HGBCL)",[35],"CAR T","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":42,"type":40},"2025-06-09",{"date":44,"type":22},"2027-12",{"name":46,"class":47},"GenomeFrontier Therapeutics TW Co., Ltd.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100511054","phase-2-pembro-plus-car-t-cell-therapy-in-rr-in-pmbcl-100511054","NCT05934448","Pembro Plus CAR T-cell Therapy in R\u002FR in PMBCL","A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed\u002FRefractory Primary Mediastinal B-cell Lymphoma","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of PMBCL, EBV+ DLBCL or THRLBCL at one of the participating institutions.\n* Availability of archival or freshly collected tumor tissue before study enrollment. If archival tissue is unavailable or is determined to be inadequate, tumor tissue must be obtained from a biopsy performed at screening, unless an exception is given after consultation with the sponsor-investigator.\n* Eligible for standard of care CAR T-cell therapy with progression after at least two prior lines of therapy OR refractory to initial chemoimmunotherapy OR relapse within 12 months of front-line chemoimmunotherapy OR one prior line of therapy and not fit for HSCT.\n* ECOG Performance Status of 0 or 1.\n* Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO).\n* Adequate hematologic function (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator), defined as follows:\n\n  * ANC ≥ 1,000\u002FμL\n  * Hemoglobin ≥ 8 g\u002FdL\n  * Platelet count ≥ 50,000\u002FμL\n* Participants must have adequate organ as defined below:\n\n  * Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver involvement)\n  * Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine clearance (by Cockcroft-Gault) ≥ 40 ml\u002Fmin for patients with serum creatinine \\>1.5 x ULN\n* At least one bi-dimensionally FDG-avid measurable lymphoma lesion on PET\u002FCT scan, defined as ≥ 1.5 cm in its longest dimension on CT scan, or ≥ 1 cm if extranodal (and measurable).\n* Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 6 months for WOCBP and for men after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control, e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, use of two forms of birth control, and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.\n* Age ≥18 years.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients in urgent need of cytoreductive therapy.\n* Participants who are receiving any other investigational agents.\n* History of other malignancies, except:\n\n  * Malignancy treated medically or surgically with curative intent and with no known active disease present for ≥2 years before study registration\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease.\n  * Localized prostate cancer and low-risk prostate cancer on active surveillance\n  * In the opinion of the treating investigator, there is limited potential to interfere with the safety or efficacy of the investigational regimen. Such exceptions must be approved by the Sponsor-Investigator.\n* Has received a live vaccine within 30 days prior to study registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n* Less than 6 months of response to prior PD-L1 inhibitor or PD-1 inhibitor or grade 3 or higher immune-related adverse events.\n* Prior treatment with CAR T-cell therapy.\n* Lactating or pregnant. Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) at screening. WOCBP will require a negative pregnancy test within 72 hours prior to starting treatment, but eligibility for study enrollment may be confirmed based on testing at screening.\n* Known active lymphomatous involvement of the central nervous system. History of prior CNS involvement is allowed.\n* Recent infection requiring intravenous antibiotics that was completed ≤7 days before the first dose of study drug, or any uncontrolled active systemic infection.\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus infection.\n* History of Human immunodeficiency virus (HIV)-infection.\n* Has received prior radiotherapy within 2 weeks of study registration. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n* Has received prior systemic anti-cancer therapy within 2 weeks or investigational agents within 4 weeks.\n* Significant liver disease, such as hepatitis (viral or non-viral) or cirrhosis\n* Prior macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH)\n* Uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months of enrollment.\n* Known history of central nervous system or neurologic disease including stroke or intracranial hemorrhage within 3 months prior to enrollment or seizure disorder. Prior CNS involvement with lymphoma is allowed if previously treated with no evidence of involvement at study entry.\n* Prior solid organ or allogeneic stem cell transplant or within 6 weeks of autologous stem cell transplant.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to study registration. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n* Active pneumonitis or interstitial lung disease.\n* Severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has not met requirements for standard of care CAR-T therapy",{"count":57,"type":22},35,[59],"PHASE2","This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment.\n\nThe names of the study drugs involved in this study are:\n\n\\- Pembrolizumab\n\nStandard treatment will include:\n\n* CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel)\n* Cyclophosphamide\n* Fludarabine",[62,63,64,65,66,67],"Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Primary Mediastinal Large B Cell Lymphoma","Primary Mediastinal Large B-Cell Lymphoma Refractory","Primary Mediastinal Large B-Cell Lymphoma Recurrent","Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma","T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma",[62,63,64,65,67,69],"Epstein-Barr virus-positive diffuse large B-cell lymphoma","2026-03-03",{"date":72,"type":40},"2026-03-05",{"date":74,"type":40},"2023-11-15",{"date":76,"type":22},"2031-06-06",{"name":78,"class":79},"Jennifer Crombie, MD","OTHER",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100532193","phase-1-cc-99282--rituximab-early-post-cart-for-non-hodgkins-lymphoma-100532193","NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information\n* Age ≥ 18 years at the time of consent\n* Diagnosis of B-cell Non-Hodgkin's lymphoma including either large B-cell lymphoma or follicular lymphoma. Large B-cell subtypes include but are not limited to diffuse large B-cell lymphoma, high grade B-cell lymphoma (except Burkitt's Lymphoma), primary mediastinal B-cell lymphoma, and diffuse large B cell lymphoma transformed from indolent lymphomas\n* Eastern Cooperative Oncology Group (ECOG) Score = 0-2\n* Prior receipt of standard of care CD19 directed CAR-T cell therapy including axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel\n* Pre-CART imaging within 90 days of infusion of CD19.CAR-T for baseline disease evaluation. If patient's receive bridging therapy, imaging evaluation post bridging therapy is encouraged as part of institutional guidelines, but not mandated for inclusion\n* Evidence of objective response on PET\u002FCT at 25-100 days post CD19.CAR-T infusion compared to baseline pre-CART imaging. Objective response in this trial is defined by reduced fludeoxyglucose F-18 (FDG) uptake or reduction in mass size and includes mixed response\n* Evidence of sub-optimal response to CD19.CAR-T as defined in this trial by Deauville Score ≥ 3 on PET\u002FCT at 25-100 days post CD19.CAR-T infusion.\n* Absolute neutrophil count ≥ 7.5 x 10\\^8\u002FL (obtained within 30 days prior to initiating study treatment)\n* Evidence of partial response, though sub-optimal response as determined by persistent MRD positivity. (Example: Deauville Score 1 or 2 is eligible if MRD is positive via clonoseq).\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Hemoglobin ≥ 8 x 10\\^9\u002FL (obtained within 30 days prior to initiating study treatment)\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Platelets ≥ 50 x 10\\^9\u002FL (obtained within 30 days prior to initiating study treatment)\n\n  * Hematological lab values should be without the use of growth factors or transfusion support\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Estimated glomerular filtration rate (eGFR) (based on chronic kidney disease-epidemiology collaboration \\[CKD-EPI\\] \\* patient's body surface area \\[BSA\\] \\[Du Bois method\\]\u002F1.73m\\^2) ≥ 45 ml\u002Fmin (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Bilirubin ≤ 1.5 × upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level \\> 2.0 mg\u002FdL if their conjugated bilirubin is \\\u003C 2.0 × ULN) (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Aspartate aminotransferase (AST) ≤ 3.0 × ULN (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Alanine aminotransferase (ALT) ≤ 3.0 × ULN (obtained within 30 days prior to initiating study treatment)\n\n  * Note: Changes in laboratory parameters during the study should not be considered adverse events unless they meet criteria for dose modification(s) of study medication outlined by the protocol and\u002For worsen from baseline during therapy\n* Patients must be able to provide adequate tissue samples for minimal residual disease (MRD) analysis for identification (ID) of baseline tumor deoxyribonucleic acid (DNA). 2 forms of tissue will be acceptable: optional baseline biopsy tissue post CART and prior to initiation of CC-99282, or archival tumor tissue (ex. formalin-fixed paraffin embedded \\[FFPE\\] tumor blocks) from a biopsy containing lymphoma prior to CD19.CART\n* Fridericia's formula-corrected QT interval (QTcF) \\\u003C 470 ms\n* Patients must be able to swallow\u002Fabsorb capsules\n* Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment. Pregnancy tests must be medically supervised with a minimum sensitivity of 25mIU\u002Fml. NOTE: a female of childbearing potential is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months, i.e. has had menses at any time in the preceding 24 consecutive months. Documentation of postmenopausal status must be provided. Further information on pregnancy testing and the definition of a female of childbearing potential located in the CC-99282 pregnancy prevention plan document\n* Females of childbearing potential are required to use 2 forms of effective methods of contraception or to agree to practice complete abstinence from the time of informed consent, without interruption, at least 28 days before starting CC-99282, throughout the entire duration of CC-99282, during dose interruptions and for at least 6 months and 2 weeks after the last dose of golcadomide (BMS-986369)\u002FCC-99282. The two contraception methods can be comprised one highly effective method and one additional effective (barrier) method. Further information on acceptable methods is located in the CC-99282 pregnancy prevention plan document\n* Male subjects with female partners must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while taking CC-99282, during dose interruptions and for at least 3 months and 2 weeks following the last dose of CC-99282, even if he has undergone a successful vasectomy. Additional information regarding prevention of pregnancy as it pertains to male subjects is contained within the CC-99282 pregnancy prevention plan document\n* Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the experimental regimen are eligible for the trial\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study and lactating females must agree to not breastfeed while taking study drugs)\n* Uncontrolled concomitant illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV), unstable angina pectoris, myocardial infarction within 1 month prior to enrollment, uncontrolled cardiac arrhythmias, uncontrolled seizures, or severe non compensated hypertension (Systolic blood pressure \\>= 180mmHg or diastolic blood pressure \\>= 120mmHg)\n* Receipt of CD19.CAR-T for any indication other than that stated within the inclusions criteria\n* Concomitant use of strong CYP3A inhibitors and inducers. Examples include (but are not limited to):\n\n  * CYP3A inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin.\n  * CYP3A inducers: carbamazepine, phenytoin, and rifampin. Patients that are able to come off moderate CYP3A inhibitors\u002Finducers will require a washout period of at least 14 days or 5 half-lives, whichever is shorter, prior to the initiation of study treatment\n* Patients who are actively receiving or have received other investigational agents, including herbal supplements, within 2 weeks or 5 half-lives of enrollment",{"count":21,"type":22},[25],"This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.",[92,93,94,95,32,96,97,98,99,100,31,101],"B-Cell Non-Hodgkin Lymphoma-Recurrent","Diffuse Large B-Cell Lymphoma-Recurrent","Follicular Lymphoma-Recurrent","High Grade B-Cell Lymphoma-Recurrent","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent","B-Cell Non-Hodgkin Lymphoma-Refractory","Diffuse Large B-Cell Lymphoma-Refractory","Follicular Lymphoma-Refractory","High Grade B-Cell Lymphoma-Refractory","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory","2026-02-24",{"date":104,"type":40},"2026-02-27",{"date":106,"type":40},"2024-01-29",{"date":108,"type":22},"2026-12-31",{"name":110,"class":79},"Nathan Denlinger"]